Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
2.760
-0.272 (-8.98%)
Sep 15, 2025, 2:16 PM EDT - Market open

Chemomab Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202018 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Net Income
-11.83-13.95-24.22-27.65-12.48-5.95
Upgrade
Depreciation & Amortization
0.060.050.070.060.030.02
Upgrade
Stock-Based Compensation
0.510.621.493.212.020.13
Upgrade
Other Operating Activities
-0.04-----
Upgrade
Change in Accounts Receivable
-0.27-0.490.9-0.06-2.06-0.1
Upgrade
Change in Accounts Payable
-0.740.15-1.170.351.180.07
Upgrade
Change in Other Net Operating Assets
-2.04-1.77-0.683.72-1.070.59
Upgrade
Operating Cash Flow
-14.34-15.39-23.61-20.37-12.37-5.24
Upgrade
Capital Expenditures
---0-0.07-0.24-0.04
Upgrade
Sale of Property, Plant & Equipment
----1-
Upgrade
Investment in Securities
3.772.315.8819.6-45.95-0.02
Upgrade
Other Investing Activities
----0-
Upgrade
Investing Cash Flow
3.772.315.8819.53-45.19-0.06
Upgrade
Issuance of Common Stock
11.059.873.50.4158.651.25
Upgrade
Repurchase of Common Stock
----1.22--
Upgrade
Other Financing Activities
----2.43-
Upgrade
Financing Cash Flow
11.059.873.5-0.8161.074.75
Upgrade
Net Cash Flow
0.49-3.22-4.23-1.653.51-0.55
Upgrade
Free Cash Flow
-14.34-15.39-23.61-20.44-12.61-5.28
Upgrade
Free Cash Flow Per Share
-2.57-3.43-8.04-7.18-4.86-3.09
Upgrade
Cash Income Tax Paid
---0.19-0.35--
Upgrade
Levered Free Cash Flow
-10.64-10.86-15.49-10.87-6.07-2.56
Upgrade
Unlevered Free Cash Flow
-10.64-10.86-15.49-10.87-6-2.56
Upgrade
Change in Working Capital
-3.04-2.11-0.954.01-1.950.56
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q